Wheat Gliadin

Monoclonal antibodies to gliadin (test sample set)



Order
Quantity
Price
Status
1 Set 600 € available


Documents
Art. No. A086
Background info The set of 10 monoclonal antibodies to gliadin, 50 μg of each mab:
A011 (XGY1), A013 (XGY7), A054 (XGY6), A056 (XGY11), A059 (XGY9), A060 (XGY10), A064 (XGY4), A067 (XGY15), A070 (XGY24), A085 (XGY19)
Host Mouse
Clone XGY1, XGY4, XGY6, XGY7, XGY9, XGY10, XGY11, XGY15, XGY19, XGY24
Isotype IgG1
Immunogen Purified wheat gliadin
Specificity Mouse monoclonal Antibody reacts specifically with: Gliadin
Appearance liquid
Reagents 75 mM NaCl, 5 mM Tris, pH7.5, 0.025% sodium azide, 50% glycerol.
Application Immunoassays; immunoblotting
Working dilutions Optimal dilutions should be determined by the end user.
The following are guidelines only: Western-Blot: 1 / 500 to 1 / 2,000.
Storage Store at -80°C.
If storage at -80°C is not possible, storage at ≤ -20°C is recommended. Stable for short term at +4°C.
Delivery is possible at ambient temperature.
Note INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification

Blog  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy